Autolus Therapeutics


Christopher Vann, Ph.D., Chief Operating Officer

April 10 | 4:00pm | Salone dei Cavalieri, Section 3&4

London, United Kingdom


Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients. Autolus is a leader in T cell programming, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.

By using this website you agree to accept our Privacy Policy and Terms & Conditions